Avoro Capital Advisors Reduces $51M in PTC Therapeutics, Inc. ($PTCT)

Avoro Capital Advisors has completely exited its position in PTCT, selling all 685,000 shares it previously held. This move, reflected in their latest Form 13F filing with the SEC, shows a 100% reduction in their holdings as of the reporting period.

What Changed in Avoro Capital Advisors' PTCT Position

Avoro Capital Advisors sold all 685,000 shares of PTCT it held, reducing its stake to zero. This marks a complete exit from the stock, as the firm previously owned 685,000 shares.

Other Institutional Activity in PTCT

While Avoro Capital Advisors exited, other major institutional investors adjusted their stakes in PTCT. BlackRock, Inc. increased its holdings by 169,652 shares, bringing its total to 12,948,717 shares valued at about $882.2 million. Janus Henderson Group PLC significantly boosted its position by adding 2,342,101 shares, ending with 7,193,433 shares worth approximately $490 million. Meanwhile, Vanguard Portfolio Management LLC initiated a new position with 4,804,594 shares valued at $327.3 million. State Street Corp also increased its stake slightly by 140,393 shares, now holding 4,346,519 shares worth $296.1 million.

PTCT Stock Snapshot

Shares of PTCT recently traded around $74.95. The stock has seen interest from several institutional investors, with varying changes in their holdings. The details of PTCT's market cap, P/E ratio, and other financial metrics were not available in the latest filing.

Insider Buying and Selling at PTC Therapeutics, Inc.

Recent insider activity at PTCT includes several planned and unplanned transactions. On June 10, 2026, Eric Pauwels, the Chief Business Officer, executed planned sales of 21,277 shares at an average price of $75.00 and 17,566 shares with no specified price. On the same day, he also bought 17,566 shares at $18.01. Additionally, on May 15, 2026, Mark Elliott Boulding, the Executive VP and CLO, sold 2,812 shares at an average price of $72.18 in a planned sale and bought the same amount at $25.69 in an unplanned transaction.

Analysts Set New Price Targets

Several analysts have recently updated their ratings and price targets for PTCT. On June 9, 2026, Citigroup assumed coverage with a buy rating and a $108.00 price target. Jefferies upgraded the stock to a buy with an $85.00 target on May 27, 2026. Earlier, on May 8, 2026, TD Cowen also upgraded PTCT to a buy, setting a target of $90.00. Wells Fargo maintained its buy rating with a $95.00 target on the same day.

Bottom Line

Avoro Capital Advisors' complete exit from PTCT reflects a strategic decision as of the first quarter of 2026. While Avoro moved out, other major funds like BlackRock and Janus Henderson adjusted their holdings, showing diverse institutional interest. Analysts continue to support PTCT with positive ratings and price targets, suggesting ongoing attention from the market. Remember, 13F filings are backward-looking and may not reflect current positions.